Next Article in Journal
Antibacterial, Antioxidant, and Antiproliferative Activities of Corymbia citriodora and the Essential Oils of Eight Eucalyptus Species
Next Article in Special Issue
Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain
Previous Article in Journal
Qigong and a Tale of Two Back Complaints
Previous Article in Special Issue
The Role of Cannabinoids in the Setting of Cirrhosis
Open AccessArticle

Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials

1
Department of Neurology, Central Hospital of Bolzano, 39100 Bolzano, Italy
2
Department of Neurology, SS Giovanni e Paolo Hospital, 30122 Venice, Italy
3
Department of Neurology, Casa di Cura Pederzoli, 37019 Peschiera del Garda, VR, Italy
4
Neurology Unit, Department of Neuroscience and Rehabilitation, S. Anna Hospital, 44124 Ferrara, Italy
5
Neurology Unit, Department of Neuroscience, AOUI Verona, 37126 Verona, Italy
*
Author to whom correspondence should be addressed.
Medicines 2018, 5(3), 59; https://doi.org/10.3390/medicines5030059
Received: 25 May 2018 / Revised: 15 June 2018 / Accepted: 19 June 2018 / Published: 21 June 2018
(This article belongs to the Special Issue Cannabinoids for Medical Use)
Background. Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) (nabiximols or Sativex®) is an oromucosal spray formulation containing THC and CBD at an approximately 1:1 fixed ratio. Its administration for the treatment of pain in patients with multiple sclerosis (MS) has been established. MS patients generally complain of different kinds of pain, including spasticity-related and neuropathic pain. In this study, we compared and evaluated pain modulation and thermal/pain threshold of MS patients before and after THC/CBD administration. Methods. 19 MS patients underwent clinical examination, numerical rating scale (NRS), quantitative sensory testing (QST), and laser-evoked potentials (LEPs) before and after 1 month of therapy. Psychophysiological and neurophysiological data were compared to sex- and age-matched controls. Results. Patients reported a significant reduction in pain. We found statistically significant differences in LEP parameters between patients and controls but no significant change in LEP measures after THC/CBD therapy. Cold and heat detection thresholds were altered in patients but did not change after THC/CBD therapy. There was a significant increase in cold pain threshold by hand stimulation and a significant reduction in abnormal cold perception thresholds. Conclusions. Our results indicate that Sativex® therapy provides pain relief in MS patients and suggest that it might modulate peripheral cold-sensitive TRP channels. View Full-Text
Keywords: pain; multiple sclerosis; oromucosal cannabinoid spray; quantitative sensory testing; laser-evoked potentials pain; multiple sclerosis; oromucosal cannabinoid spray; quantitative sensory testing; laser-evoked potentials
Show Figures

Figure 1

MDPI and ACS Style

Turri, M.; Teatini, F.; Donato, F.; Zanette, G.; Tugnoli, V.; Deotto, L.; Bonetti, B.; Squintani, G. Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials. Medicines 2018, 5, 59.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop